Hemolytic-uremic syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Line 22: | Line 22: | ||
| doi = 10.5049/EBP.2013.11.1.9 | | doi = 10.5049/EBP.2013.11.1.9 | ||
| pmid = 23946760 | | pmid = 23946760 | ||
}}</ref> | }}</ref><ref>{{cite journal|doi=10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+}}</ref> | ||
*Supportive therapy and hydration | *Supportive therapy and hydration | ||
*Obsereved closely | *Obsereved closely | ||
*Use eculizumab in aHUS | |||
==References== | ==References== |
Revision as of 19:24, 17 August 2018
Hemolytic-uremic syndrome Microchapters |
Differentiating Hemolytic-uremic syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hemolytic-uremic syndrome secondary prevention On the Web |
American Roentgen Ray Society Images of Hemolytic-uremic syndrome secondary prevention |
Risk calculators and risk factors for Hemolytic-uremic syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
Effective measures for the secondary prevention of HUS include:[1][2][3]
- Supportive therapy and hydration
- Obsereved closely
- Use eculizumab in aHUS
References
- ↑ Grisaru, Silviu (2014). "Management of hemolytic-uremic syndrome in children". International Journal of Nephrology and Renovascular Disease: 231. doi:10.2147/IJNRD.S41837. ISSN 1178-7058.
- ↑ Hoon Young Choi & Sung Kyu Ha (2013). "Potassium balances in maintenance hemodialysis". Electrolyte & blood pressure : E & BP. 11 (1): 9–16. doi:10.5049/EBP.2013.11.1.9. PMID 23946760. Unknown parameter
|month=
ignored (help) - ↑ . doi:10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+ Check
|doi=
value (help). Missing or empty|title=
(help)